flanders.bio announces upcoming changes in its staff

 

flanders.bio today announced that Henk Joos, Chief Executive Officer, resigned and will depart from the organisation on March 1, 2018. A search for a new Chief Executive Officer has started. Under the interim management of Willem Dhooge, the organisation will continue to execute its updated strategy announced at the last general assembly meeting. Chairman Erwin Blomsma and Vice Chairman Dirk Reyn will assist Willem and the flanders.bio team until a new CEO joins flanders.bio.

Over the past years, flanders.bio has moved from a missionary role representing, promoting and connecting biotechnology companies to a more content driven organisation and key player in the life sciences ecosystem.


Dirk Reyn, Vice Chairman said: “We want to thank Henk very much for all his effort in further growing flanders.bio since he took over. These efforts have resulted in a growing attendance at our events like knowledge for growth; the expansion of the scope of our activities and an even broader global network of partners. All of this has been key in further strengthening the life sciences ecosystem in Flanders.”


Erwin Blomsma, Chairman: “With the new strategy, we have started to strengthen capabilities at different levels of our organisation and we have set certain priorities in order to be successful. This made parties recognise that a different profile of CEO may be best for the organisation going forward. Henk can be proud of the progress the team has made and we are sure he will find a new role within our ecosystem.”

Note

flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise.

flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.

flanders.bio is supported by a number of strategic partners: VIB, Janssen Pharmaceutica, Roche Diagnostics, KBC Securities, Deloitte, CMAST, Flanders Investment & Trade, Agentschap Innoveren & Ondernemen and Gimv.

For more info, please visit www.flanders.bio.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?